Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price targ...
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price ta...
Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $55 price target.
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.15) per share which met the analyst consensus estimate. Th...
VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurosci...
Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $55 price target.
